Radiotherapy (RT) Patterns of Care Study (PCS) in Lung Carcinoma
Reviewer: William Levin, MD
Last Modified: October 9, 2002
Presenter: B. Movsas
Presenter's Affiliation: Fox Chase Cancer Center (FCCC), Phila, PA, USA
Type of Session: Scientific
- This study was designed to determine the national patterns of radiation therapy (RT) practice in patients treated for non-metastatic lung cancer between 1998-1999.
Materials and Methods
- A survey of randomly selected RT institutions was conducted. Both academic and non-academic institutions were surveyed.
- Patients with non-metastatic lung cancer who received RT as definitive or adjuvant therapy were randomly selected.
- The charts of 541 patients were reviewed.
- 58 institutions were represented.
- 14.5% of histologies were small cell lung cancer (SCLC), while the remainder were non-small cell lung cancer (NSCLC).
- Median age was 67 years (37-92).
- 58% of patients were male, while 42% were female.
- 32% of patients were current smokers.
- 59% of patients had co-morbidities, mostly cardiopulmonary.
- KPS was >80 in 84% of patients.
- 98% of patients had staging CT scans.
- In CS III patients, bone scans and brain MRI's were not obtained in 33% and 52%, respectively.
- For NSCLC, a breakdown by clinical stage (CS) is as follows: CS I-12%, CS II-16%, CS III-54% (4% unknown).
- For patients with NSCLC, 31% had their mediastinums pathologically staged.
- Treatment strategies varied significantly by histology and stage.
- The majority of patients with SCLC and stage III NSCLCA received chemotherapy (CT) + RT.
- Most patients with CS I NSCLC received RT as their only treatment.
- Median dose for RT in the SCLC patients was 51 Gy, 80% at 1.8-2 Gy/fraction; 10% received hyperfractionated (b.i.d.) RT.
- 23% of these patients received prophylactic cranial irradiation (median dose, 30 Gy/15 fractions).
- For NSCLC, the median dose was 60 Gy, 85% @ 1.8-2 Gy/fraction.
- The majority of patients were treated with 6MV or 10 MV photons.
- CT-based treatment planning was used in 50% of patients.
- Maximum spinal cord dose was 41 Gy, although the dose was unknown in 29%.
- 57% of patients received systemic treatment.
- Surgery was performed in 28% of NSCLC patients.
- 5% of all patients were enrolled on cooperative trials, and 2% on institutional (IRB-approved) trials.
- This study establishes the general patterns of care for lung cancer in U.S. RT facilities.
- Better staging and documentation of spinal cord dose should be encouraged.
- The authors point out recent studies supporting the use of PCI and b.i.d. RT in SCLC have not had enough time to fully be reflected in a patterns of care study.
- Also, this study reveals that a small percentage of lung cancer patients are being enrolled on clinical trials.
Oncolink's ASTRO Coverage made possible by an unrestricted Educational Grant from Ortho Biotech.